Xsensio Advances Next-Generation Wearable Health Monitoring
Propel(x) portfolio company Xsensio continues to advance its Lab-on-Skin® platform, achieving several important milestones in wearable biosensing and continuous health monitoring.
The company recently closed an oversubscribed $7 million Series A financing round led by WI Harper Group, providing additional resources to accelerate technology development and commercialization efforts.
Xsensio also announced a long-term collaboration with Texas Instruments to support the development of next-generation wearable biosensing solutions. The collaboration aims to strengthen sensor integration and improve the performance of continuous monitoring devices.
Leadership Participation at LSX Europe
CEO and Co-Founder Esmeralda Megally recently represented Xsensio at LSX Europe in Lisbon, joining industry leaders to discuss the future of personalized, data-driven healthcare and the growing role of continuous health monitoring technologies.
Advancing the Lab-on-Skin® Platform
Xsensio is developing a skin-worn device designed to continuously monitor multiple health indicators from a single platform. The technology seeks to provide real-time health insights through non-invasive sensing, with potential applications across:
- Hospital care
- Patient recovery monitoring
- Remote patient monitoring
- Personalized healthcare management
The company continues to progress toward first-in-human studies, an important step in validating its wearable biosensing platform.
Expanding Strategic Collaborations
Xsensio has established collaborations with several leading healthcare and research organizations, including:
- Roche
- EPFL
- CHUV
- Charité – Universitätsmedizin Berlin
- Institut Gustave Roussy
These collaborations support the continued development and validation of Xsensio’s wearable health technologies.
Industry Recognition
In recognition of its innovation in digital health, Xsensio was named one of TIME’s World’s Top HealthTech Companies 2025. The recognition highlights the company’s growing role in advancing wearable technologies for continuous health monitoring.
As Xsensio progresses toward clinical validation and commercialization, the company continues to contribute to the evolution of personalized healthcare and next-generation wearable biosensing solutions.
Propel(x) congratulates Esmeralda Megally and the entire Xsensio team on these achievements and looks forward to following the company’s continued progress.
Learn more about Xsensio and discover innovative healthcare companies by visiting Propel(x).
